Related Experiment Videos
[Current treatment for malignant lymphomas]
1Division of Clinical Oncology and Hematology, Dept. of Internal Medicine, The Jikei University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 15, 2007
Summary
New treatments like rituximab improve outcomes for follicular lymphoma and diffuse large B cell lymphoma. Standard chemotherapy (ABVD) remains key for Hodgkin Lymphoma, while novel strategies offer hope for aggressive cases.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Context:
- Hodgkin Lymphoma (HL), follicular lymphoma (FL), and diffuse large B cell lymphoma (DLBCL) are common malignant lymphomas.
- Treatment decisions rely on international prognostic indexes and current therapeutic strategies.
Purpose:
- To outline optimal treatment strategies for common lymphoma subtypes.
- To highlight advancements in lymphoma therapy, including immunotherapy.
Summary:
- For newly diagnosed HL, ABVD chemotherapy is standard to cure disease and minimize late toxicities.
- Rituximab (RIT), an anti-CD20 antibody, improves FL outcomes when combined with chemotherapy.
- R-CHOP (rituximab plus CHOP chemotherapy) is the standard for newly diagnosed DLBCL, outperforming CHOP alone.
- Novel strategies combining RIT with intensive chemotherapy (e.g., EPOCH) show promise for poor-prognosis DLBCL patients.
Impact:
- Rituximab significantly enhances treatment efficacy for FL and DLBCL.
- Optimized chemotherapy regimens reduce long-term side effects in HL patients.
- Emerging therapies offer improved outcomes for patients with aggressive or poor-prognosis lymphomas.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...